The company continues to operate without revenue, reporting an operating loss of $18.0 million in 2026Q1 while stock-based compensation expenses reached $182.8 million.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 41.42M | 29.7M | 26.69M | 45.03M | 25.51M | 14.54M | 6.64M | 1.61M | 713.94K | 682.43K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.3B | 4.48M | 6.7M | 6.24M | 9M | 6.06M | 3.59M | 829.37K | 602.33K | 409.06K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 16.74B | 25.22M | 20M | 38.79M | 16.52M | 8.48M | 3.05M | 776.26K | 111.61K | 273.37K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -1000K | 0 | 0 | 0 | 0 | 0 | 0 | 378 | 0 | 0 |
| Operating Income | -41.42M | -29.7M | -26.69M | -45.03M | -25.51M | -14.54M | -6.64M | -1.61M | -714K | -682K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -11.24% | 40.72% | -76.53% | -75.49% | -118.93% | -313.46% | -124.93% | -4.69% | - |
| EBITDA | -41.42M | -29.7M | -26.69M | -45.03M | -25.51M | -14.5M | 0 | 0 | -63 | 433 |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -64.59% | -11.24% | 40.72% | -76.53% | -75.93% | - | - | 100% | -114.55% | - |
| D&A (Non-Cash Add-back) | 3 | 0 | 0 | 0 | 0 | 0 | 6.64M | 1.61M | 713.94K | 682.43K |
| EBIT | -41.42M | -29.7M | -26.69M | -45.03M | -25.51M | -14.5M | -6.64M | -1.61M | -714K | -682K |
| Net Interest Income | 649.25K | 699.06K | -1.52M | 667.9K | 182.71K | 13.34K | -47.18M | 0 | 0 | 0 |
| Interest Income | 649.25K | 699.06K | 331.85K | 667.9K | 182.71K | 13.34K | 47.23K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 1.85M | 0 | 0 | 0 | 47.23M | 0 | 66 | 84 |
| Other Income/Expense | 501.25K | 841.06K | 2.1M | -11.17M | 182.71K | 50.09K | 1.18M | 614.64K | 66 | 84 |
| Pretax Income | -40.92M | -28.85M | -24.59M | -56.2M | -25.33M | -14.49M | -5.46M | -991K | -714K | -682K |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -132 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.02% | 0% |
| Net Income | -40.92M | -28.85M | -24.59M | -56.2M | -25.33M | -14.49M | -5.46M | -991K | -714K | -682K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -40.82% | -17.34% | 56.25% | -121.9% | -74.83% | -165.23% | -451.17% | -38.8% | -4.69% | - |
| Net Income (Continuing) | -40.92M | -28.85M | -24.59M | -56.2M | -25.33M | -14.49M | -5.46M | -991K | -714K | -682K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.47 | -1.40 | -2009.77 | -6.23 | -3.10 | -1.90 | -0.87 | -0.17 | -0.16 | -0.16 |
| EPS Growth % | 26.5% | 99.93% | -32159.55% | -100.97% | -63.16% | -118.39% | -411.76% | -6.25% | 0% | - |
| EPS (Basic) | - | -1.40 | -2018.50 | -6.23 | -3.10 | -1.90 | -0.87 | -0.17 | -0.16 | -0.16 |
| Diluted Shares Outstanding | 27.85M | 20.55M | 12.23M | 9.02M | 8.16M | 7.63M | 6.31M | 6.84M | 4.4M | 4.39M |
| Basic Shares Outstanding | 27.85M | 20.55M | 12.18M | 9.02M | 8.16M | 7.63M | 6.31M | 6.84M | 4.4M | 4.39M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Binary clinical trial failure
As reported in recent financial filings, Annovis Bio's research and development expenditures reached $16.7 billion in 2026Q1, a figure that significantly outpaces historical quarterly averages and highlights the aggressive capital consumption required to advance the company's lead compound, Buntanetap, through late-stage clinical trial milestones.
The dramatic spike in R&D spending suggests that the company has entered a high-intensity phase of clinical execution, likely tied to patient enrollment and site management costs. Investors should monitor whether this level of expenditure is sustainable given the company's limited cash reserves, as such costs appear to be the primary driver of the current net loss trajectory.
Based on the company's income statement data, stock-based compensation reached $182.8 million in 2026Q1, representing a substantial non-cash expense that complicates the interpretation of the firm's underlying operational efficiency and obscures the true cash burn rate associated with its ongoing neurodegenerative research programs.
The magnitude of this non-cash charge relative to historical periods warrants further investigation into the company's compensation strategy and its potential impact on shareholder dilution. Analysts should adjust for these items to better understand the actual cash runway available for clinical operations, as the reported net loss may not fully reflect the liquidity constraints facing the organization.
According to the provided income statement history, Annovis Bio continues to operate without revenue, resulting in an operating loss of $18.0 million in 2026Q1, which underscores the company's total reliance on external financing to fund its research-heavy business model and lack of scalable commercial operations.
The absence of revenue means that operating leverage cannot be realized until the company successfully transitions to a commercial-stage entity. Until such a transition occurs, the firm's operating losses will likely continue to scale in direct proportion to the complexity and scope of its clinical trial activities.
As indicated by the company's financial statements, the combination of a $19.5 million cash balance and accelerating quarterly losses suggests that Annovis Bio faces a critical liquidity inflection point that may necessitate dilutive equity financing or a strategic partnership to ensure the completion of its Phase 3 trials.
Short-term observers may focus on the potential for a capital raise, which could significantly dilute existing shareholders if the company fails to secure non-dilutive funding. The market appears to be pricing in this binary risk, as the current valuation reflects skepticism regarding the firm's ability to reach commercialization without further substantial capital infusions.
Quick answers to the most common questions about buying ANVS stock.
For fiscal year 2025, Annovis Bio, Inc. (ANVS) reported total revenue of $0.0M.
Annovis Bio, Inc. (ANVS) reported a net loss of $28.9M for the fiscal year ending 2025.